Cereno Scientific AB (publ) announced that the company will join the PVRI Roundtable (Pulmonary and Vascular Research Institute). Cereno will, amongst other things, participate in PVRI's Innovative Drug Development Initiative (IDDI), addressing the most challenging issues faced by pharma, researchers, regulators, and clinicians and join a task force to stimulate awareness of new research in Pulmonary Hypertension. The collaboration comes on the back of Cereno's participation at the PVRI Annual World Congress on Pulmonary Vascular Disease and The PVRI Drug Discovery & Development Symposium.

By joining the PVRI Roundtable, Cereno will be able to further increase the exposure for the Company's pipeline, comprising late-stage Phase II drug candidate CS1, a HDAC inhibitor with epigenetic effects for the treatment of the rare disease PAH, CS014, an HDAC inhibitor with epigenetic effect, being developed for thrombosis prevention with a first-in-human Phase I study planned to start in second quarter 2024 and the Company's 3rd asset CS585, a novel IP receptor agonist. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.